When prostate cancer becomes resistant to traditional hormone therapies, new treatment approaches are needed.
Pfizer researchers are studying EZH2 and exploring ways to potentially reprogram treatment resistance in metastatic prostate cancer.
Learn more: on.pfizer.com/4hbgke2
00:00

